Differential effects of donor-specific HLA antibodies in living versus deceased donor transplant

E G Kamburova, B W Wisse, I Joosten, W A Allebes, A van der Meer, L B Hilbrands, M C Baas, E Spierings, C E Hack, F E van Reekum, A D van Zuilen, M C Verhaar, M L Bots, A C A D Drop, L Plaisier, M A J Seelen, J S F Sanders, B G Hepkema, A J A Lambeck, L B Bungener, C Roozendaal, M G J Tilanus, C E Voorter, L Wieten, E M van Duijnhoven, M Gelens, M H L Christiaans, F J van Ittersum, S A Nurmohamed, N M Lardy, W Swelsen, K A van der Pant, N C van der Weerd, I J M Ten Berge, F J Bemelman, A Hoitsma, P J M van der Boog, J W de Fijter, M G H Betjes, S Heidt, D L Roelen, F H Claas, H G Otten, E G Kamburova, B W Wisse, I Joosten, W A Allebes, A van der Meer, L B Hilbrands, M C Baas, E Spierings, C E Hack, F E van Reekum, A D van Zuilen, M C Verhaar, M L Bots, A C A D Drop, L Plaisier, M A J Seelen, J S F Sanders, B G Hepkema, A J A Lambeck, L B Bungener, C Roozendaal, M G J Tilanus, C E Voorter, L Wieten, E M van Duijnhoven, M Gelens, M H L Christiaans, F J van Ittersum, S A Nurmohamed, N M Lardy, W Swelsen, K A van der Pant, N C van der Weerd, I J M Ten Berge, F J Bemelman, A Hoitsma, P J M van der Boog, J W de Fijter, M G H Betjes, S Heidt, D L Roelen, F H Claas, H G Otten

Abstract

The presence of donor-specific anti-HLA antibodies (DSAs) is associated with increased risk of graft failure after kidney transplant. We hypothesized that DSAs against HLA class I, class II, or both classes indicate a different risk for graft loss between deceased and living donor transplant. In this study, we investigated the impact of pretransplant DSAs, by using single antigen bead assays, on long-term graft survival in 3237 deceased and 1487 living donor kidney transplants with a negative complement-dependent crossmatch. In living donor transplants, we found a limited effect on graft survival of DSAs against class I or II antigens after transplant. Class I and II DSAs combined resulted in decreased 10-year graft survival (84% to 75%). In contrast, after deceased donor transplant, patients with class I or class II DSAs had a 10-year graft survival of 59% and 60%, respectively, both significantly lower than the survival for patients without DSAs (76%). The combination of class I and II DSAs resulted in a 10-year survival of 54% in deceased donor transplants. In conclusion, class I and II DSAs are a clear risk factor for graft loss in deceased donor transplants, while in living donor transplants, class I and II DSAs seem to be associated with an increased risk for graft failure, but this could not be assessed due to their low prevalence.

Keywords: alloantibody; clinical research/practice; graft survival; kidney failure/injury; kidney transplantation; kidney transplantation/nephrology; living donor.

© 2018 The Authors. American Journal of Transplantation published by Wiley Periodicals, Inc. on behalf of The American Society of Transplantation and the American Society of Transplant Surgeons.

Figures

Figure 1
Figure 1
Prevalence of pretransplant HLA‐Abs and donor‐specific HLA antibodies (DSAs) in the total cohort (N = 4724). A. Venn diagram showing the prevalence of pretransplant HLA‐A/B/DR/DQ HLA‐Abs. B. Venn diagram showing the prevalence of pretransplant HLA‐A/B/DR/DQDSAs [Color figure can be viewed at http://www.wileyonlinelibrary.com]
Figure 2
Figure 2
Long‐term graft survival of kidney transplants according to the presence of pretransplant donor‐specific HLA antibodies (DSAs). A. Adjusted Kaplan–Meier estimates (AKME) for death‐censored graft survival according to the presence of pretransplant DSAs for the total cohort including deceased‐ and living‐donor transplants (N = 4724). B. AKME for death‐censored graft survival according to the presence of pretransplant DSAs for living‐donor transplants only (n = 1487). C. AKME for death‐censored graft survival according to the presence of pretransplant DSAs for deceased‐donor transplants only (n = 3237). All AKME were adjusted for the same covariates: recipient age (quadratic) and donor age (quadratic), donor type (living or deceased; for the total cohort only), cold ischemia time (for donation after brain death [DBD] and donation after cardiac death [DCD]), time on dialysis in years (quadratic), and induction therapy with interleukin‐2 receptor blocker [Color figure can be viewed at http://www.wileyonlinelibrary.com]
Figure 3
Figure 3
Impact of donor‐specific HLA antibodies (DSAs) on graft survival for deceased‐donor transplants. A. Adjusted Kaplan–Meier estimates (AKME) for 1‐year death‐censored graft survival according to the presence of pretransplant DSAs for living‐donor transplants only (n = 1487). B. AKME for 1‐year death‐censored graft survival according to the presence of pretransplant DSAs for deceased‐donor transplants only (n = 3237). C. Analysis of long‐term effect of pretransplant DSAs starting at 1 year after transplant for living‐donor transplants only (n = 1417). D. Analysis of long‐term effect of pretransplant DSAs starting at 1 year after transplant for deceased‐donor transplants only (n = 2834). E. AKME for death‐censored graft survival according to the presence of pretransplant HLA class I (A/B) and/or II (DR/DQ) DSAs for living‐donor transplants only (n = 1487). F. AKME for death‐censored graft survival according to the presence of pretransplant HLA class I (A/B) and/or II (DR/DQ) DSAs for deceased‐donor transplants only (n = 3237). All AKME were adjusted for the same covariates: recipient age (quadratic) and donor age (quadratic), donor type (living or deceased; for the total cohort only), cold ischemia time (for donation after brain death [DBD] and donation after cardiac death [DCD]), time on dialysis in years (quadratic) and induction therapy with interleukin‐2 receptor blocker [Color figure can be viewed at http://www.wileyonlinelibrary.com]

References

    1. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LYC, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341(23):1725‐1730.
    1. Sayegh MH, Carpenter CB. Transplantation 50 years later–progress, challenges, and promises. N Engl J Med. 2004;351(26):2761‐2766.
    1. Ojo AO, Morales JMM, González‐Molina M, et al. Comparison of the long‐term outcomes of kidney transplantation: USA versus Spain. Nephrol Dial Transplant. 2013;28(1):213‐220.
    1. Brenner H, Opelz G, Gondos A, Do B. Kidney graft survival in Europe and the United States: strikingly different long‐term outcomes. Transplantation. 2013;95(2):267‐274.
    1. Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol. 2005;16(10):3015‐3026.
    1. Pascual M, Theruvath T, Kawai T, Tolkoff‐Rubin N, Cosimi AB. Strategies to improve long‐term outcomes after renal transplantation. N Engl J Med. 2002;346(8):580‐590.
    1. Sayegh MH. Why do we reject a graft? role of indirect allorecognition in graft rejection. Kidney Int. Elsevier Masson SAS; 1999;56(5):1967‐1979.
    1. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med. 1969;280(14):735‐739.
    1. Couzi L, Araujo C, Guidicelli G, et al. Interpretation of positive flow cytometric crossmatch in the era of the single‐antigen bead assay. Transplantation. 2011;91(5):527‐535.
    1. Aubert V, Venetz JP, Pantaleo G, Pascual M. Low levels of human leukocyte antigen donor‐specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant. Hum Immunol 2009;70(8):580‐583.
    1. Salvadé I, Aubert V, Venetz J, et al. Clinically‐relevant threshold of preformed donor‐specific anti‐HLA antibodies in kidney transplantation. Hum Immunol 2016;77:483‐489.
    1. Vaidya S, Partlow D, Susskind B, Noor M, Barnes T, Gugliuzza K. Prediction of crossmatch outcome of highly sensitized patients by single and/or multiple antigen bead Luminex assay. Transplantation. 2006;82(11):1524‐1528.
    1. Mizutani K, Terasaki P, Hamdani E, et al. The importance of anti‐HLA‐specific antibody strength in monitoring kidney transplant patients. Am J Transplant. 2007;7(4):1027‐1031.
    1. Tait BD, Süsal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non‐HLA antibodies in transplantation. Transplantation. 2013;95(1):19‐47.
    1. Amico P, Hönger G, Mayr M, Steiger J, Hopfer H, Schaub S. Clinical relevance of pretransplant donor‐specific HLA antibodies detected by single‐antigen flow‐beads. Transplantation. 2009;87(11):1681‐1688.
    1. Laging M, Kal‐van GJ, Haasnoot GW, et al. Transplantation results of completely HLA‐mismatched living and completely HLA‐matched deceased‐donor kidneys are comparable. Transplantation 2014;97(3):330‐336.
    1. Loupy A, Lefaucheur C, Vernerey D, et al. Complement‐binding anti‐HLA antibodies and kidney‐allograft survival. N Engl J Med. 2013;369(13):1215‐1226.
    1. Lachmann N, Terasaki PI, Budde K, et al. Anti‐human leukocyte antigen and donor‐specific antibodies detected by Luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation. 2009;87(10):1505‐1513.
    1. Mohan S, Palanisamy A, Tsapepas D, et al. Donor‐specific antibodies adversely affect kidney allograft outcomes. J Am Soc Nephrol. 2012;23(12):2061‐2071.
    1. Ushigome H, Harada S, Nakao M, et al. Living‐donor kidney transplantation with existing anti‐donor specific antibodies at a Japanese single center. Transplant Proc. 2015;47(3):612‐616.
    1. Orandi BJ, Garonzik‐Wang JM, Massie AB, et al. Quantifying the risk of incompatible kidney transplantation: a multicenter study. Am J Transplant 2014;14(7):1573‐1580.
    1. Haririan A, Nogueira J, Kukuruga D, et al. Positive cross‐match living donor kidney transplantation: longer‐term outcomes. Am J Transplant 2009;9(3):536‐542.
    1. Otten HG, Verhaar MC, Borst HPE, Hené RJ, van Zuilen AD. Pretransplant donor‐specific HLA class I and II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant. 2012;12(6):1618‐1623.
    1. Otten HG, Joosten I, Allebes W a, et al. The PROCARE consortium: toward an improved allocation strategy for kidney allografts. Transpl Immunol 2014;31(4):184‐190.
    1. Kamburova EG, Wisse BW, Joosten I, et al. How can we reduce costs of solid‐phase multiplex‐bead assays used to determine anti‐HLA antibodies? HLA. 2016;88(3):110‐119.
    1. Xie J, Liu C. Adjusted Kaplan‐Meier estimator and log‐rank test with inverse probability of treatment weighting for survival data. Stat Med. 2005;24(20):3089‐3110.
    1. Reinsmoen NL, Lai C‐H, Vo A, et al. Acceptable donor‐specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation. 2008;86(6):820‐825.
    1. Sicard A, Ducreux S, Rabeyrin M, et al. Detection of C3d‐binding donor‐specific anti‐HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. J Am Soc Nephrol. 2015;26(2):457‐467.
    1. Viglietti D, Loupy A, Vernerey D, et al. Value of donor‐specific anti‐HLA antibody monitoring and characterization for risk stratification of kidney allograft loss. J Am Soc Nephrol 2017;28:702‐715.
    1. Heidt S, Witvliet MD, Haasnoot GW, Claas FHJ. The 25th anniversary of the Eurotransplant Acceptable Mismatch program for highly sensitized patients. Transpl Immunol 2015;33(2):51‐57.
    1. Dunn TB, Noreen H, Gillingham K, et al. Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant. 2011;11(10):2132‐2143.
    1. Süsal C, Opelz G. Current role of human leukocyte antigen matching in kidney transplantation. Curr Opin Organ Transplant. 2013;18(4):438‐444.
    1. Roodnat JI, van Riemsdijk IC, Mulder PGH, et al. The superior results of living‐donor renal transplantation are not completely caused by selection or short cold ischemia time: a single‐center, multivariate analysis. Transplantation. 2003;75(12):2014‐2018.
    1. Hönger G, Krähenbühl N, Dimeloe S, Stern M, Schaub S, Hess C. Inter‐individual differences in HLA expression can impact the CDC crossmatch. Tissue Antigens. 2015;85(4):260‐266.
    1. Koo DDH, Welsh KI, McLaren AJ, Roake JA, Morris PJ, Fuggle SV. Cadaver versus living donor kidneys: impact of donor factors on antigen induction before transplantation. Kidney Int 1999;56(4):1551‐1559.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅